Skip to content

Clinical trials

Primary Myelofibrosis trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Primary Myelofibrosis Country / region: China Clear all

37 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20102
20111
20151
20161
20192
20201
20219
20222
20235
20244
20252
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed12
Recruiting8
Active, not recruiting8
Terminated5
Not yet recruiting2
Withdrawn1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.10
Suzhou Zelgen Biopharmaceuticals Co.,Ltd6
Incyte Corporation4
Celgene3
Novartis Pharmaceuticals3
First Affiliated Hospital of Zhejiang University2
Hangzhou GluBio Pharmaceutical Co., Ltd.1
Karyopharm Therapeutics Inc1
Nanfang Hospital, Southern Medical University1
Peking University People's Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Primary Myelofibrosis37
Myeloproliferative Disorders8
Myelodysplastic Syndromes3
Polycythemia Vera3
Thrombocythemia, Essential3
Leukemia, Myeloid, Acute2
Anemia1
Bronchiolitis Obliterans Syndrome1
Graft vs Host Disease1
Hematologic Neoplasms1

Trials

Showing 51 to 37 of 37. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.